Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Quince Therapeutics ( (QNCX) ) has provided an update.
On July 16, 2025, Quince Therapeutics announced the completion of patient enrollment for its pivotal Phase 3 NEAT clinical trial, which evaluates the eDSP treatment for Ataxia-Telangiectasia. This milestone positions Quince closer to potentially offering the first market treatment for this rare neurodegenerative disease, with topline results expected in early 2026 and a possible NDA submission in the latter half of 2026.
The most recent analyst rating on (QNCX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.
Spark’s Take on QNCX Stock
According to Spark, TipRanks’ AI Analyst, QNCX is a Underperform.
Quince Therapeutics faces substantial financial challenges with no revenue, consistent losses, and negative cash flows, severely impacting its financial performance score. Technical analysis provides mixed signals, with some indicators suggesting potential momentum but overall bearish trends. Valuation remains unattractive due to the negative P/E ratio and lack of dividend yield. The absence of earnings call and corporate events data limits further insights.
To see Spark’s full report on QNCX stock, click here.
More about Quince Therapeutics
Quince Therapeutics, Inc. is a late-stage biotechnology company focused on developing treatments for rare diseases by leveraging a patient’s own biology.
Average Trading Volume: 383,514
Technical Sentiment Signal: Buy
Current Market Cap: $80.93M
For an in-depth examination of QNCX stock, go to TipRanks’ Overview page.